| Sunday | ||||
Piper Sandler analyst… Piper Sandler analyst Edward Tenthoff lowered the firm's price target on Gamida Cell to $7 from $8 and keeps an Overweight rating on the shares. The analyst notes Gamida Cell issued 12.9 million shares at $1.55 raising gross proceeds $20 million. Additionally, Highbridge Capital provided a $25 million senior secured, 24-month term loan with a 7.5% coupon convertible at $2.22. Tenthoff estimates Gamida Cell now has pro forma cash of $97 million, owes Highbridge $97 million, and has 74.38 million shares outstanding. He remains confident in omidubicel approval for allo-HSCT by the January 30th PDUFA date based on positive Phase III data showing reductions in time to neutrophil and platelet engraftment, infection and hospital stay. | ||||
| Thursday | ||||
Biotech Analysts, along… Biotech Analysts, along with Chief Medical & Chief Scientific Officer Simantov of Gamida Cell, discuss innovations in hematopoietic stem cell transplantation on an Analyst/Industry webinar to be held on September 29 at 3 pm. Webcast Link | ||||
Gamida Cell announced the… Gamida Cell announced the presentation of new long term follow-up data and health-related quality of life scores of patients treated with omidubicel at the Tenth Annual Meeting of the Society of Hematologic Oncology, or SOHO, being held in Houston, Texas. The long-term, durable clinical benefit of omidubicel was observed at three years across a patient population that typically has a poor prognosis. A study highlighted long-term follow-up of 105 patients transplanted with omidubicel between 2006-2020. The data demonstrated an overall survival and disease-free survival of 63% and 56% at three years, respectively, as well as durable long-term hematopoiesis and immune competence. Overall well-being health-related quality of life scores for patients treated with omidubicel demonstrated clinical benefit compared to standard of care. A study featured an analysis of 108 patients that completed validated health-related quality of life surveys on screening and days 42, 100, 180, and 365 post-transplant. Measures of physical and functional well-being and other HRQL scores were more favorable with omidubicel. These data suggest clinically meaningful and sustained improvements in physical, functional, and overall well-being compared to umbilical cord blood transplantation. | ||||
Biotech Analysts, along… Biotech Analysts, along with Chief Medical & Chief Scientific Officer Simantov of Gamida Cell, discuss innovations in hematopoietic stem cell transplantation on an Analyst/Industry webinar to be held on September 29 at 3 pm. Webcast Link | ||||
| Wednesday | ||||
The deal priced below… The deal priced below last closing price of $1.96. Piper Sandler and JMP Securities are acting as joint book running managers for the offering. | ||||
| Over a week ago | ||||
Check out this evening's…
| ||||
Gamida Cell Ltd.… Gamida Cell Ltd. announced the launch of a follow-on public offering of its ordinary shares. Gamida Cell intends to use the net proceeds from this offering, together with its existing cash and cash equivalents and trading financial assets: to fund (i) commercial readiness activities to support potential launch of omidubicel, if approved; (ii) the continued clinical development of its NK product candidates, including GDA-201; and (iii) general corporate purposes, including general and administrative expenses and working capital. Piper Sandler & Co. and JMP Securities, a Citizens Company, are acting as joint book-running managers for this offering. | ||||
Biotech Analysts, along… Biotech Analysts, along with Chief Medical & Chief Scientific Officer Simantov of Gamida Cell, discuss innovations in hematopoietic stem cell transplantation on an Analyst/Industry webinar to be held on September 29 at 3 pm. Webcast Link | ||||
Gamida Cell announced… Gamida Cell announced that Abigail Jenkins has joined as president and CEO. Jenkins has also been appointed to Gamida Cell's board of directors. Jenkins succeeds Julian Adams, who is retiring in accordance with planned succession and will continue to serve on the company's board of directors. Jenkins brings over 20 years of experience in the biopharmaceutical industry. She served as the chief commercial and business officer at Lyndra Therapeutics, where she established and led global commercial, business development, corporate strategy and portfolio management across multiple therapeutic areas. | ||||
| Over a month ago | ||||
Piper Sandler analyst… Piper Sandler analyst Edward Tenthoff raised the firm's price target on Gamida Cell to $8 from $6 and keeps an Overweight rating on the shares. The FDA has set a PDUFA date of January 30 for omidubicel for allogeneic hematopoietic stem cell transplant, or aHSCT, and he remains confident in omidubicel approval based on positive Phase 3 data, said Tenthoff, who cites decreasing his discount rate on omidubicel and rolling forward his discount period to mid-2023 for his increased price target. | ||||
